HORIZON-JU-IHI-2024-06-two-stage

Suggested coordinators

Organisations that coordinated the most funded projects under this call.

• ERASMUS MC1 coordinated
• RISE1 coordinated

Strong partners

Frequent participants in this call’s funded projects (research, universities, public bodies, and mixed types).

• IRIS2 projects · FR
• Novo Nordisk2 projects · DK
• PFIZER INC2 projects · US
• PFIZER2 projects · UK
• Pfizer R&D UK Limited2 projects · UK
• ERASMUS MC1 projects · NL
• RISE1 projects · SE
• A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE SRL1 projects · IT
• ABBOTT GMBH1 projects · DE
• UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 projects · NL

Industry partners

Companies and SMEs that appear often in this call’s historical projects.

• IRIS2 projects · company
• Novo Nordisk2 projects · company
• PFIZER INC2 projects · company
• PFIZER2 projects · company
• Pfizer R&D UK Limited2 projects · company
• A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE SRL1 projects · company
• ABBOTT GMBH1 projects · company
• ACTELION PHARMACEUTICALS LTD1 projects · company
• AMGEN1 projects · company
• sanofi-aventis1 projects · company
• BAYER AKTIENGESELLSCHAFT1 projects · company
• BIOCORP1 projects · sme

Typical consortium size

Derived from historical funded projects linked to this call.

Partners per project

median 48.5 · avg 48.5

range 41 – 56 organisations

Country spread (sample)

18 countries

46–51 partner organisations (from median 48.5 in this call’s projects) · 18 countries appear often in the participant sample

Similar past projects

Largest EU contributions in this call — useful references for consortium patterns.

• GREG€13,298,375
• CAREPATH€11,300,000